BamSEC and AlphaSense Join Forces
Learn More

Protagonist Therapeutics Inc.

NASDAQ: PTGX    
Share price (1/3/25): $39.57    
Market cap (1/3/25): $2.358 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 10-Q 29 pages Third Amendment to Lease
12/34/56
EX-10.1
from 10-Q 125 pages [***] = Certain Confidential Information Contained in This Document, Marked by Brackets, Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential
12/34/56
EX-10.1
from 10-Q 11 pages Protagonist Therapeutics, Inc. Pre-Funded Warrant to Purchase Common Stock
12/34/56
EX-10.26
from 10-K 6 pages Employee Severance Agreement
12/34/56
EX-10.25
from 10-K 4 pages ​ November 1, 2022 Arturo Molina [Mailing Address] [Telephone Number] [Email Address] Dear Arturo,
12/34/56
EX-10.1
from 10-Q 3 pages ​ March 25, 2022 Asif Ali [Email Address] [Telephone Number] Dear Asif,
12/34/56
EX-10.3
from 10-Q 12 pages Second Amendment to Lease
12/34/56
EX-10.2
from 10-Q 6 pages Execution Version Arbitration Resolution Agreement Made Effective as of August 4th, 2021 (“Effective Date”)
12/34/56
EX-10.1
from 10-Q 120 pages Amended and Restated License and Collaboration Agreement
12/34/56
EX-10.1
from 10-Q 6 pages Employee Severance Agreement
12/34/56
EX-10.1
from 8-K 25 pages Protagonist Therapeutics, Inc. Amended and Restated 2018 Inducement Plan Adopted by the Board of Directors: May 29, 2018 Effective Date: May 29, 2018 as Amended On: February 18, 2020
12/34/56
EX-10.1
from 8-K 41 pages Open Market Sale Agreementsm
12/34/56
EX-10.1
from 10-Q 6 pages Employee Severance Agreement
12/34/56
EX-10.1
from 10-Q 47 pages First Amendment to the License and Collaboration Agreement
12/34/56
EX-10.1
from 8-K 3 pages Material contract
12/34/56
EX-10.1
from 8-K 10 pages May 7, 2019 Richard S. Shames, M.D. Re: Separation Agreement
12/34/56
EX-10.4
from 10-Q 7 pages Employee Severance Agreement
12/34/56
EX-10.3
from 10-Q 3 pages First Amendment to Lease
12/34/56
EX-10.1
from 8-K 6 pages December 21, 2018 Protagonist Therapeutics, Inc. 7707 Gateway Blvd., Suite 140 Newark, California 94560-1160 Attn: Dinesh V. Patel, Ph. D., President and Chief Executive Officer Re: 3(a)(9) Exchange Agreement Ladies and Gentlemen
12/34/56
EX-10.1
from S-3 23 pages Securities Purchase Agreement
12/34/56